Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) fell 2.6% during mid-day trading on Tuesday . The company traded as low as $1.43 and last traded at $1.49. 211,045 shares traded hands during trading, a decline of 56% from the average session volume of 474,548 shares. The stock had previously closed at $1.53.
Tiziana Life Sciences Trading Up 1.3%
The stock's fifty day moving average price is $1.49 and its 200-day moving average price is $1.14.
Institutional Trading of Tiziana Life Sciences
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Dauntless Investment Group LLC acquired a new stake in shares of Tiziana Life Sciences during the 1st quarter worth approximately $1,879,000. Geode Capital Management LLC increased its holdings in shares of Tiziana Life Sciences by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 245,722 shares of the company's stock worth $171,000 after buying an additional 27,041 shares during the last quarter. Jane Street Group LLC increased its holdings in Tiziana Life Sciences by 968.2% in the 1st quarter. Jane Street Group LLC now owns 167,542 shares of the company's stock valued at $181,000 after purchasing an additional 151,858 shares during the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Tiziana Life Sciences in the 1st quarter valued at approximately $156,000. Finally, Bison Wealth LLC acquired a new stake in Tiziana Life Sciences in the 4th quarter valued at approximately $30,000.
Tiziana Life Sciences Company Profile
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Recommended Stories
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
